Case Studies

Founded in August 2021 by SV Health Investors with SV Venture Partner and repeat entrepreneur, David Guyer, M.D., and Tony Adamis, M.D, EyeBio Limited (“EyeBio”) is a biotechnology company developing next-generation therapeutics for major eye diseases including diabetic macular edema (DME) and age-related macular degeneration (AMD), two leading causes of vision loss globally.

The Dementia Discovery Fund (DDF) was launched in 2015 to invest exclusively in pioneering research and drug development to tackle neurodegenerative diseases, incl. Alzheimer’s, one of the largest unmet medical needs with over 55m patients worldwide and nearly 10m new cases every year.

OrganOx is at the forefront of changing the way donor organs are preserved in the critical time between donation and transplantation. OrganOx accessed venture capital via the Enterprise Capital Funds (ECF) programme, which it used to fund the clinical studies to secure market approval for its product, a complex class III medical device.

Founded in 2019, Quell Therapeutics is a leader in engineered T-regulatory (Treg) cell therapies for medical conditions driven by abnormal immune responses.

Launched in 2013, Cambridge Innovation Capital (CIC) invests in deep-tech and life sciences businesses that have a connection with the Cambridge ecosystem.

Magnitude Biosciences, a specialist contract research organisation (CRO) in County Durham offering in vivo discovery of treatments for age-related conditions and other diseases using C. elegans, secured over £706,000 in combined funding to scale up its high-throughput screening (HTS) platform

Ori Biotech’s mission is to eliminate barriers to patient access of cell and gene therapies (CGTs) through the use of innovation and by rethinking how those therapies are manufactured.

Part of a cluster of biotech companies in Aberdeen, Elasmogen uses its bespoke technology platform to isolate innovative drugs for treating cancers and auto-immune diseases.